Suzanne Lentzsch, MD, PhD, is a Professor of Clinical Medicine and Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University, New York, NY. After gaining an MD and PhD from the Humboldt University and Charité Universitätsmedizin Berlin in Berlin, Germany, where she also completed a residency and fellowship, Prof. Lentzsch undertook a fellowship at the Dana-Farber Cancer Institute, Boston, MA. In 2004, Prof. Lentzsch joined the University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, PA, and served as Clinical Director of the Multiple Myeloma Program.
Prof. Lentzsch also serves as a Southwest Oncology Group (SWOG) Myeloma Committee Member and SWOG Study Coordinator.
Speaking on amyloidosis and multiple myeloma
Prof. Lentzsch is currently leading several clinical trials for patients with amyloidosis, newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma. Prof. Lentzsch previously served as a Principal Investigator for a study which evaluated the role of lenalidomide in the treatment of relapsed/refractory multiple myeloma, and is involved in an international trial investigating the role of Xofigo.